{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T06:52:50Z","timestamp":1781851970751,"version":"3.54.5"},"reference-count":81,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2004,4,1]],"date-time":"2004-04-01T00:00:00Z","timestamp":1080777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2004,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Learning Objectives<\/jats:title>\n                  <jats:p>After completing this course, the reader will be able to:<\/jats:p>\n                  <jats:p>Describe the mechanism of thrombosis in CVCs. Explain the symptoms, signs, and sequelae of CVC thrombosis. Discuss the evidence supporting the prophylaxis of CVC thrombosis.<\/jats:p>\n                  <jats:p>Access and take the CME test online and receive one hour of AMA PRA category 1 credit at http:\/\/CME.TheOncologist.com<\/jats:p>\n                  <jats:p>Central venous catheters (CVCs), such as the tunneled catheters and the totally implanted ports, play a major role in general medicine and oncology. Aside from the complications (pneumothorax, hemorrhage) associated with their initial insertion, all of these CVCs are associated with the long-term risks of infection and thrombosis. Despite routine flushing with heparin or saline, 41% of CVCs result in thrombosis of the blood vessel, and this markedly increases the risk of infection. Only one-third of these clots are symptomatic.<\/jats:p>\n                  <jats:p>Within days of insertion, almost all CVCs are coated with a fibrin sheath, and within 30 days, most CVC-related thrombi arise. Aside from reducing the function of the catheter, these CVC-related thrombi can cause postphlebitic syndrome in 15%\u201330% of cases and pulmonary embolism in 11% (only half of which are symptomatic).<\/jats:p>\n                  <jats:p>Risk factors for CVC thrombosis include the type of malignancy, type of chemotherapy, type of CVC, and locations of insertion site and catheter tip, but not inherited thrombophilic risk factors. Efforts to reduce CVC thrombosis with systemic prophylactic anticoagulation with low-molecular-weight heparin have failed. Low-dose warfarin prophylaxis remains controversial; all studies are flawed, with older studies, but not newer ones, showing benefit.<\/jats:p>\n                  <jats:p>Currently, less than 10% of patients with CVCs receive any systemic prophylaxis. Although its general use cannot be recommended, low-dose warfarin may be a low-risk treatment in patients with good nutrition and adequate hepatic function. Clearly, additional studies are required to substantiate the prophylactic use of low-dose warfarin. Newer anticoagulant treatments, such as pentasaccharide and direct thrombin inhibitors, need to be explored to address this major medical problem.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.9-2-207","type":"journal-article","created":{"date-parts":[[2004,8,24]],"date-time":"2004-08-24T21:38:39Z","timestamp":1093383519000},"page":"207-216","source":"Crossref","is-referenced-by-count":184,"title":["Thrombotic Complications of Central Venous Catheters in Cancer Patients"],"prefix":"10.1093","volume":"9","author":[{"given":"David J.","family":"Kuter","sequence":"first","affiliation":[{"name":"Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2004,4,1]]},"reference":[{"key":"2021122209311160700_R1","doi-asserted-by":"crossref","DOI":"10.5479\/sil.126677.39088002685501","volume-title":"Exercitatio Anatomica du Motu Cordis et Sanguinis in Animlibus","author":"Harvey","year":"1628"},{"key":"2021122209311160700_R2","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/00033797300200071","article-title":"A study of Parentalia, with two unpublished letters of Sir Christopher Wren","volume":"30","author":"Bennett","year":"1973","journal-title":"Ann Sci"},{"key":"2021122209311160700_R3","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1017\/S0025727300021803","article-title":"A note on theories of respiration and muscular action in England c. 1660 (Christopher Wren)","volume":"20","author":"Bennett","year":"1976","journal-title":"Med Hist"},{"key":"2021122209311160700_R4","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/00000542-199001000-00026","article-title":"Early intravenous anesthesia: an eyewitness account","volume":"72","author":"Bergman","year":"1990","journal-title":"Anesthesiology"},{"key":"2021122209311160700_R5","first-page":"274","article-title":"[Christopher Wren and the discovery of intravenous injections.]","volume":"66","author":"Buess","year":"1973","journal-title":"Z Krankenpfl"},{"key":"2021122209311160700_R6","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1055\/s-2000-8797","article-title":"[History of injections. Pictures from the history of otorhinolaryngology highlighted by exhibits of the German History of Medicine Museum in Ingolstadt.]","volume":"79","author":"Feldmann","year":"2000","journal-title":"Laryngorhinootologie"},{"key":"2021122209311160700_R7","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1213\/00000539-197453060-00008","article-title":"Historical vignettes. Sir Christopher Wren","volume":"53","author":"Keys","year":"1974","journal-title":"Anesth Analg"},{"key":"2021122209311160700_R8","first-page":"26","article-title":"A historical review of the illustrations of the circle of Willis from antiquity to 1664","volume":"25","author":"Kenney","year":"1998","journal-title":"J Biocommun"},{"key":"2021122209311160700_R9","volume-title":"Tractatus de Corde","author":"Lower","year":"1669"},{"key":"2021122209311160700_R10","volume-title":"Prodromus Inventae a se Chirurgiae Infusoriae","author":"Major","year":"1664"},{"key":"2021122209311160700_R11","volume-title":"Chirurgia Infusoria. Kiel","author":"Major","year":"1667"},{"key":"2021122209311160700_R12","volume-title":"Clysmatica Nova, Sive Ratio, Qua in Venam Sectam Medicamenta Immitti Possint","author":"Elsholtz","year":"1667"},{"key":"2021122209311160700_R13","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1001\/archsurg.1971.01350040115023","article-title":"Fibrin sleeve formation on indwelling subclavian central venous catheters","volume":"102","author":"Hoshal","year":"1971","journal-title":"Arch Surg"},{"key":"2021122209311160700_R14","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/0720-048X(95)00633-2","article-title":"Central venous catheter-related thrombosis in clinically asymptomatic oncologic patients: a phlebographic study","volume":"20","author":"Balestreri","year":"1995","journal-title":"Eur J Radiol"},{"key":"2021122209311160700_R15","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0049-3848(97)00054-6","article-title":"Central venous thrombosis: an early and frequent complication in cancer patients bearing long-term silastic catheter. A prospective study","volume":"86","author":"Cicco","year":"1997","journal-title":"Thromb Res"},{"key":"2021122209311160700_R16","first-page":"481","article-title":"Fibrin sleeve formation after long term brachial catheterisation with an implantable port device. A prospective venographic study","volume":"158","author":"Starkhammar","year":"1992","journal-title":"Eur J Surg"},{"key":"2021122209311160700_R17","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1001\/jama.1994.03510370066034","article-title":"The relationship between the thrombotic and infectious complications of central venous catheters","volume":"271","author":"Raad","year":"1994","journal-title":"JAMA"},{"key":"2021122209311160700_R18","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1093\/infdis\/168.2.400","article-title":"Ultrastructural analysis of indwelling vascular catheters: a quantitative relationship between luminal colonization and duration of placement","volume":"168","author":"Raad","year":"1993","journal-title":"J Infect Dis"},{"key":"2021122209311160700_R19","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1001\/archinte.1986.00360220101019","article-title":"Adherent microorganisms on lumenal surfaces of long-term intravenous catheters. Importance of Staphylococcus epidermidis in patients with cancer","volume":"146","author":"Tenney","year":"1986","journal-title":"Arch Intern Med"},{"key":"2021122209311160700_R20","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1111\/j.1365-2044.1996.tb14972.x","article-title":"A review of 560 Hickman catheter insertions","volume":"51","author":"Ray","year":"1996","journal-title":"Anaesthesia"},{"key":"2021122209311160700_R21","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s10434-000-0441-y","article-title":"Transcutaneously tunneled central venous lines in cancer patients: an analysis of device-related morbidity factors based on prospective data collection","volume":"7","author":"Schwarz","year":"2000","journal-title":"Ann Surg Oncol"},{"key":"2021122209311160700_R22","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1378\/chest.95.1.71","article-title":"Thrombosis: the major Hickman catheter complication in patients with solid tumor","volume":"95","author":"Anderson","year":"1989","journal-title":"Chest"},{"key":"2021122209311160700_R23","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1001\/archsurg.1980.01380020078018","article-title":"Restoring patency of occluded central venous catheters","volume":"115","author":"Hurtubise","year":"1980","journal-title":"Arch Surg"},{"key":"2021122209311160700_R24","first-page":"29","article-title":"The use of urokinase to restore patency of occluded central venous catheters","volume":"9","author":"Lawson","year":"1982","journal-title":"Am J Intraven Ther Clin Nutr"},{"key":"2021122209311160700_R25","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/0002-9343(93)90312-D","article-title":"Groshong catheter-associated subclavian venous thrombosis","volume":"95","author":"Gould","year":"1993","journal-title":"Am J Med"},{"key":"2021122209311160700_R26","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1177\/014860719501900175","article-title":"Are clinical signs accurate indicators of the cause of central venous catheter occlusion?","volume":"19","author":"Stephens","year":"1995","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"2021122209311160700_R27","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1046\/j.1365-2141.1998.00732.x","article-title":"Prevention of central venous catheter associated thrombosis using minidose warfarin in patients with haematological malignancies","volume":"101","author":"Boraks","year":"1998","journal-title":"Br J Haematol"},{"key":"2021122209311160700_R28","doi-asserted-by":"crossref","first-page":"3665","DOI":"10.1200\/JCO.2000.18.21.3665","article-title":"Physician compliance with warfarin prophylaxis for central venous catheters in patients with solid tumors","volume":"18","author":"Carr","year":"2000","journal-title":"J Clin Oncol"},{"key":"2021122209311160700_R29","first-page":"235","article-title":"Catheter-related thrombosis in patients with refractory lymphoma undergoing autologous stem cell transplantation","volume":"7","author":"Conlan","year":"1991","journal-title":"Bone Marrow Transplant"},{"key":"2021122209311160700_R30","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1445-5994.1996.tb02904.x","article-title":"Hickman catheters: left-sided insertion, male gender, and obesity are associated with an increased risk of complications","volume":"26","author":"Craft","year":"1996","journal-title":"Aust N Z J Med"},{"key":"2021122209311160700_R31","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1007\/BF00187683","article-title":"Subcutaneous ports in the radiology suite: an effective and safe procedure for care in cancer patients","volume":"6","author":"Gregorio","year":"1996","journal-title":"Eur Radiol"},{"key":"2021122209311160700_R32","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/1097-0142(20010215)91:4<806::AID-CNCR1068>3.0.CO;2-K","article-title":"Central venous device-related infection and thrombosis in patients treated with moderate dose continuous-infusion interleukin-2","volume":"91","author":"Eastman","year":"2001","journal-title":"Cancer"},{"key":"2021122209311160700_R33","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1200\/JCO.1995.13.1.233","article-title":"Complications of indwelling venous access devices in cancer patients","volume":"13","author":"Eastridge","year":"1995","journal-title":"J Clin Oncol"},{"key":"2021122209311160700_R34","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s002620050386","article-title":"Tunnelled central venous catheters yield a low incidence of septicaemia in interleukin-2-treated patients","volume":"44","author":"Goey","year":"1997","journal-title":"Cancer Immunol Immunother"},{"key":"2021122209311160700_R35","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/jca.2920050404","article-title":"Thrombotic complications of subclavian apheresis catheters in cancer patients: prevention with heparin infusion","volume":"5","author":"Haire","year":"1990","journal-title":"J Clin Apheresis"},{"issue":"suppl 3","key":"2021122209311160700_R36","doi-asserted-by":"crossref","first-page":"S147","DOI":"10.1007\/PL00014342","article-title":"Clinical importance of prothrombotic risk factors in pediatric patients with malignancy\u2014impact of central venous lines","volume":"158","author":"Knofler","year":"1999","journal-title":"Eur J Pediatr"},{"key":"2021122209311160700_R37","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S1072-7515(00)00690-6","article-title":"Longterm central venous access in gynecologic cancer patients","volume":"191","author":"Minassian","year":"2000","journal-title":"J Am Coll Surg"},{"issue":"suppl 3","key":"2021122209311160700_R38","doi-asserted-by":"crossref","first-page":"S143","DOI":"10.1007\/PL00014341","article-title":"Clinical relevance of genetic risk factors for thrombosis in paediatric oncology patients with central venous catheters","volume":"158","author":"Wermes","year":"1999","journal-title":"Eur J Pediatr"},{"key":"2021122209311160700_R39","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1046\/j.1445-5994.2002.00171.x","article-title":"Minidose (1 mg) warfarin as prophylaxis for central vein catheter thrombosis","volume":"32","author":"Heaton","year":"2002","journal-title":"Intern Med J"},{"key":"2021122209311160700_R40","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3109\/08880019509029565","article-title":"Central venous catheter clots: incidence, clinical significance and catheter care in patients with hematologic malignancies","volume":"12","author":"Barzaghi","year":"1995","journal-title":"Pediatr Hematol Oncol"},{"key":"2021122209311160700_R41","doi-asserted-by":"crossref","first-page":"423","DOI":"10.7326\/0003-4819-76-3-112-6-423","article-title":"Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial","volume":"112","author":"Bern","year":"1990","journal-title":"Ann Intern Med"},{"key":"2021122209311160700_R42","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/0049-3848(95)00041-0","article-title":"Antithrombin III deficiency as a risk factor for catheter-related central vein thrombosis in cancer patients","volume":"78","author":"Cicco","year":"1995","journal-title":"Thromb Res"},{"key":"2021122209311160700_R43","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1067\/mpd.2001.111272","article-title":"Catheter-related thrombosis in children with cancer","volume":"138","author":"Glaser","year":"2001","journal-title":"J Pediatr"},{"key":"2021122209311160700_R44","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/BF02303635","article-title":"Venographic surveillance of tunneled venous access devices in adult oncology patients","volume":"2","author":"Horne","year":"1995","journal-title":"Ann Surg Oncol"},{"key":"2021122209311160700_R45","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1055\/s-0038-1648910","article-title":"Upper extremity impedance plethysmography in patients with venous access devices","volume":"72","author":"Horne","year":"1994","journal-title":"Thromb Haemost"},{"key":"2021122209311160700_R46","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1055\/s-0038-1650254","article-title":"Upper extremity deep venous thrombosis in cancer patients with venous access devices\u2014prophylaxis with a low molecular weight heparin (Fragmin)","volume":"75","author":"Monreal","year":"1996","journal-title":"Thromb Haemost"},{"key":"2021122209311160700_R47","first-page":"59","article-title":"[Experimental prevention of deep venous thrombosis with low-molecular-weight heparin using implantable infusion devices.]","volume":"45","author":"Pucheu","year":"1996","journal-title":"Ann Cardiol Angeiol (Paris)"},{"key":"2021122209311160700_R48","first-page":"369a","article-title":"A phase III randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of daily low-molecular-weight heparin (dalteparin sodium, fragmin) in preventing catheter-related complications (CRCs) in cancer patients with central venous catheter (CVCs)","volume":"21","author":"Reichardt","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122209311160700_R49","first-page":"285","article-title":"Dynamics of thrombophlebitis in central venous catheterization via basilic and cephalic veins","volume":"150","author":"Curelaru","year":"1984","journal-title":"Acta Chir Scand"},{"key":"2021122209311160700_R50","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1002\/1097-0142(19831101)52:9<1586::AID-CNCR2820520908>3.0.CO;2-4","article-title":"Subclavian vein thrombosis in patients treated with infusion chemotherapy for advanced malignancy","volume":"52","author":"Lokich","year":"1983","journal-title":"Cancer"},{"key":"2021122209311160700_R51","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/00005792-198407000-00001","article-title":"Hickman catheter infections in patients with malignancies","volume":"63","author":"Press","year":"1984","journal-title":"Medicine (Baltimore)"},{"key":"2021122209311160700_R52","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1200\/JCO.2000.18.6.1269","article-title":"Prevention of central venous catheter-related infections and thrombotic events in immunocompromised children by the use of vancomycin\/ciprofloxacin\/heparin flush solution: a randomized, multicenter, double-blind trial","volume":"18","author":"Henrickson","year":"2000","journal-title":"J Clin Oncol"},{"key":"2021122209311160700_R53","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/0049-3848(95)00125-B","article-title":"Reductions in tissue plasminogen activator and thrombomodulin in blood draining veins damaged by venous access devices","volume":"79","author":"Horne","year":"1995","journal-title":"Thromb Res"},{"key":"2021122209311160700_R54","first-page":"250","article-title":"[Upper extremity deep venous thrombosis","volume":"25","author":"Massoure","year":"2000","journal-title":"J Mal Vasc"},{"key":"2021122209311160700_R55","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1001\/archinte.1997.00440220061008","article-title":"Upper-extremity deep vein thrombosis. Risk factors, diagnosis, and complications","volume":"157","author":"Prandoni","year":"1997","journal-title":"Arch Intern Med"},{"key":"2021122209311160700_R56","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1378\/chest.99.2.280","article-title":"Upper-extremity deep venous thrombosis and pulmonary embolism. A prospective study","volume":"99","author":"Monreal","year":"1991","journal-title":"Chest"},{"key":"2021122209311160700_R57","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000046591","article-title":"Thrombotic complications of central venous catheters in cancer patients","volume":"106","author":"Monreal","year":"2001","journal-title":"Acta Haematol"},{"key":"2021122209311160700_R58","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/00062752-199704050-00002","article-title":"Venous thromboembolism in the cancer patient","volume":"4","author":"Durica","year":"1997","journal-title":"Curr Opin Hematol"},{"key":"2021122209311160700_R59","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1634\/theoncologist.4-6-443","article-title":"Cancer, coagulation, and anticoagulation","volume":"4","author":"Letai","year":"1999","journal-title":"The Oncologist"},{"key":"2021122209311160700_R60","first-page":"437","article-title":"Cancer and venous thromboembolism: an overview","volume":"84","author":"Prandoni","year":"1999","journal-title":"Haematologica"},{"key":"2021122209311160700_R61","first-page":"117","article-title":"Thrombosis and cancer","volume":"48","author":"Valente","year":"2000","journal-title":"Minerva Cardioangiol"},{"key":"2021122209311160700_R62","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/ajh.1070","article-title":"Hypercoagulability states in upper-extremity deep venous thrombosis","volume":"67","author":"Leebeek","year":"2001","journal-title":"Am J Hematol"},{"key":"2021122209311160700_R63","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1002\/1097-0142(19900901)66:5<900::AID-CNCR2820660515>3.0.CO;2-A","article-title":"Hickman catheter-induced thoracic vein thrombosis. Frequency and long-term sequelae in patients receiving high-dose chemotherapy and marrow transplantation","volume":"66","author":"Haire","year":"1990","journal-title":"Cancer"},{"key":"2021122209311160700_R64","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S0959-8049(97)89012-0","article-title":"A prospective analysis of 949 long-term central venous access catheters for ambulatory chemotherapy in patients with gastrointestinal malignancy","volume":"33","author":"Nightingale","year":"1997","journal-title":"Eur J Cancer"},{"key":"2021122209311160700_R65","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1001\/archsurg.1987.01400230066012","article-title":"Reliability of implantable central venous access devices in patients with cancer","volume":"122","author":"Stanislav","year":"1987","journal-title":"Arch Surg"},{"key":"2021122209311160700_R66","first-page":"543","article-title":"Tunneled catheter thrombosis: factors related to incidence","volume":"17","author":"Brown-Smith","year":"1990","journal-title":"Oncol Nurs Forum"},{"issue":"suppl 1","key":"2021122209311160700_R67","first-page":"310S","article-title":"Covalent antithrombin-heparin complex coated catheter prevents thrombosis in a rabbit central venous catheter model","volume":"86","author":"Chan","year":"2001","journal-title":"Thromb Haemost"},{"key":"2021122209311160700_R68","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0955-3886(97)00008-8","article-title":"Normal saline versus heparin flush for maintaining central venous catheter patency during apheresis collection of peripheral blood stem cells (PBSC)","volume":"18","author":"Stephens","year":"1997","journal-title":"Transfus Sci"},{"key":"2021122209311160700_R69","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1378\/chest.113.1.165","article-title":"Benefit of heparin in central venous and pulmonary artery catheters: a meta-analysis of randomized controlled trials","volume":"113","author":"Randolph","year":"1998","journal-title":"Chest"},{"key":"2021122209311160700_R70","doi-asserted-by":"crossref","first-page":"132S","DOI":"10.1378\/chest.119.1_suppl.132S","article-title":"Prevention of venous thromboembolism","volume":"119","author":"Geerts","year":"2001","journal-title":"Chest"},{"key":"2021122209311160700_R71","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1378\/chest.119.1_suppl.3S","article-title":"Grades of recommendation for antithrombotic agents","volume":"119","author":"Guyatt","year":"2001","journal-title":"Chest"},{"key":"2021122209311160700_R72","doi-asserted-by":"crossref","first-page":"1S","DOI":"10.1378\/chest.119.1_suppl.1S","article-title":"The sixth (2000) ACCP guidelines for antithrombotic therapy for prevention and treatment of thrombosis. American College of Chest Physicians","volume":"119","author":"Hirsh","year":"2001","journal-title":"Chest"},{"key":"2021122209311160700_R73","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1001\/archinte.162.16.1833","article-title":"Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies","volume":"162","author":"Turpie","year":"2002","journal-title":"Arch Intern Med"},{"key":"2021122209311160700_R74","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1001\/archinte.163.11.1337","article-title":"Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study","volume":"163","author":"Eriksson","year":"2003","journal-title":"Arch Intern Med"},{"key":"2021122209311160700_R75","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1056\/NEJMoa011100","article-title":"Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery","volume":"345","author":"Eriksson","year":"2001","journal-title":"N Engl J Med"},{"key":"2021122209311160700_R76","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1056\/NEJMoa011099","article-title":"Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery","volume":"345","author":"Bauer","year":"2001","journal-title":"N Engl J Med"},{"key":"2021122209311160700_R77","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1046\/j.1538-7836.2003.00368.x","article-title":"Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study","volume":"1","author":"Colwell","year":"2003","journal-title":"J Thromb Haemost"},{"key":"2021122209311160700_R78","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1046\/j.1365-2796.2003.01225.x","article-title":"Oral direct thrombin inhibitors in clinical development","volume":"254","author":"Gustafsson","year":"2003","journal-title":"J Intern Med"},{"key":"2021122209311160700_R79","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0002-8703(03)00325-9","article-title":"Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V)","volume":"146","author":"Halperin","year":"2003","journal-title":"Am Heart J"},{"key":"2021122209311160700_R80","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1046\/j.1538-7836.2003.00034.x","article-title":"A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I","volume":"1","author":"Eriksson","year":"2003","journal-title":"J Thromb Haemost"},{"key":"2021122209311160700_R81","first-page":"S5","article-title":"Two new antithrombotic agents (fondaparinux and ximelagatran) and their implications in anesthesia","volume":"49","author":"Moerloose","year":"2002","journal-title":"Can J Anaesth"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.9-2-207","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.9-2-207","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/9\/2\/207\/41844506\/oncolo_9_2_207.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/9\/2\/207\/41844506\/oncolo_9_2_207.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T16:25:35Z","timestamp":1640190335000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/9\/2\/207\/6387906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4,1]]},"references-count":81,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2004,4,1]]},"published-print":{"date-parts":[[2004,4,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.9-2-207","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2004,4,1]]},"published":{"date-parts":[[2004,4,1]]}}}